In 2013, Diazon Pharmaceuticals teamed up with The Laboratory for Therapeutic Development (LTD) to identify the mechanism of action of a potential new anticancer agent called DZ-2384. Members of the LTD, Dr. Joseph Tcherkezian, Cynthia Bernier, Dr. Yannève Rolland and Claude Godbout carried out functional genomic screens to identify the anti-mitotic mechanism. They then went on to characterize its unique effects on microtubule dynamics compared with other anti-mitotics as well as to determine the activity of the compound in several mouse tumor models. The study, published in Science Translational Medicine, was led by Drs. Anne Roulston and Gordon Shore along with Dr. Gary Brouhard Dept of Biology, and includes as collaborators GCRC members Drs. Peter Siegel and George Zogopoulos as well as several international labs.
Microtubule targeting agents (MTAs) form the basis of many chemotherapeutic regimens currently used in the treatment of solid tumors and leukemias. These agents, which include taxanes (paclitaxel, docetaxel) and vinca alkaloids (vinblastine and vinorelbine), are accompanied by toxic side effects including peripheral neuropathy, which often results in a reduction or delay in dosing and can leave lasting effects on patients after therapy has been completed.
This study uncovers the unique mechanism by which DZ-2384 is very effective at targeting cancer cells by inhibiting mitosis, yet preserves the microtubule network in non-dividing cells including primary neurons resulting in a superior safety margin in rodent models. By analyzing the high resolution structure of tubulin with different compounds, the study demonstrates that DZ-2384 binds at the vinca site but induces a distinctive change in the curvature of tubulin protofilaments compared to vincas, which may explain its unusual effects on microtubule dynamics and decreased toxicity.
The way that DZ-2384 and vincas interact with tubulin sheds light on the role that tubulin protofilament curvature plays in microtubule dynamics and provides structural insight into the design of improved microtubule targeting agents that are safer for patients. [2016 November 17].